MET and neoplasm: Emerging evidence indicates that tivantinib, a c-Met inhibitor, improves median time to progression; patients with higher c-Met (3+, 2+ IHC staining in at least 50% of tumor cells) are known to have a longer time to progression with tivantinib treatment [4, 25].